PIK3CA mutation and clinicopathological features of colorectal cancer: a systematic review and Meta-Analysis

Figures & data

Figure 1. A flow chart of the study selection process.

Table 1. Overall analysis of the association between PIK3CA mutation and clinicopathological features in CRC patients.

Factors	Number of trails	Number of patients	OR	95% CI	I^2, Phet	Begg	Egger
Demographic characteristics
Age (≥60 Years)
All	7	3191	1.26	0.99-1.59	19%,0.28	0.23	0.155
Exon 20	3	968	1.2	0.51-2.84	0%,0.63	0.296	0.309
Gender (Male)
All	32	14977	0.93	0.84-1.02	35%,0.03	0.884	0.927
Exon 9	7	4879	0.97	0.80-1.18	66%,0.007	0.23	0.132
Exon 20	10	6580	1.27	1.00-1.63	0%,0.66	0.371	0.125
Clinical Factures
Disease stage (Stage III-IV)
All	20	8974	1.00	0.88-1.14	38%,0.05	0.163	0.139
Exon 9	3	2776	1.01	0.78-1.32	0%,0.49	1	0.377
Exon 20	6	4469	0.77	0.57-1.04	0%,0.45	0.06	0.231
T stage (T 3-4)
All	12	5722	1.10	0.88-1.37	0%,0.95	0.451	0.905
Exon 9	3	1417	1.37	0.75-2.48	0%,0.775	1	0.5
Exon 20	4	2507	0.72	0.42-1.23	0%,0.70	1	0.794
Metastasis(Yes)
All	6	1836	0.90	0.38-2.1	81%,<0.0001	0.707	0.481
Tumor site (Proximal)
All	10	6317	1.79	1.39-2.29	57%,0.01	0.858	0.946
Exon 9	5	3460	1.78	1.18-2.68	61%,0.03	0.462	0.523
Exon 20	5	3460	1.61	1.05-2.45	33%,0.2	1	0.938
Tumor differentiation (Poor)
All	19	7762	1.03	0.85-1.24	18%,0.23	0.675	0.766
Exon 9	3	1987	0.93	0.64-1.35	44%,0.17	1	0.83
Exon 20	4	3097	1.20	0.75-1.93	0%,0.95	1	0.943
Histology (Mucinous)
All	11	4349	1.86	1.50-2.31	0%,0.8	0.64	0.242
Molecular Features
KRAS (Mutation)
All	15	6448	2.06	1.78-2.38	0%,0.56	0.276	0.303
Exon 9	6	4255	2.32	1.88-2.85	0%,0.57	0.452	0.71
Exon 20	6	4255	1.51	1.13-2.01	8%,0.36	0.707	0.33
BRAF (mutation)
All	11	5974	0.92	0.73-1.16	0%,0.64	1	0.386
Exon 9	6	4408	0.69	0.49-0.96	42%,0.12	1	0.598
Exon 20	6	4408	1.61	1.13-2.31	0%,0.77	0.707	0.502
MSI status (High)
All	9	5050	1.59	1.02-2.48	72%,<0.00001	0.118	0.634
Exon 9	5	4167	0.71	0.51-0.99	0%,0.79	0.806	0.732
Exon 20	7	4745	2.43	1.77-3.34	0%,0.73	0.548	0.643
MMR (dMMR)
All	3	2181	2.06	0.94-4.52	75%,0.02	1	0.668

CI: confidence interval; MSI: microsatellite instability; dMMR: deficient mismatch repair capacity; pMMR: proficient mismatch repair capacity. The bold value represents the related clinicopathological parameter has statistical significance.

Figure 2. The association of PIK3CA mutation with tumor characteristics, including tumor site (A), tumor differentiation (B) and mucinous histology (C).

Figure 3. The association of PIK3CA mutation with molecular features, including KRAS mutation status (A), BRAF mutation status (B), MSI status (C), and MMR capacity (D).